News 2023-06-23
Porton Pharma Solutions Launches State-of-the-Art Small Molecule Platform in Shanghai, Elevating CDMO Services
We are thrilled to announce the establishment of our state-of-the-art Small Molecule Platform in Shanghai, revolutionizing our CDMO services. With this exciting development, Porton Pharma Solutions Ltd. now have seven R&D and production facilities in Shanghai that are equipped to provide comprehensive solutions for drug substance, drug preparation, synthetic macromolecules, and biological macromolecules.
As a trusted partner in the pharmaceutical industry, we understand the evolving needs of our clients and the importance of seamless integration throughout the drug development process. With our Small Molecule Platform, we offer a one-stop-shop solution, combining our expertise, cutting-edge facilities, and advanced technologies to accelerate and streamline the development of small molecule-based therapeutics.
This groundbreaking development reinforces our commitment to be at the forefront of CDMO services and empower our clients with the tools and expertise needed to succeed in the fast-paced pharmaceutical landscape. We are excited to collaborate with innovators, researchers, and pharmaceutical companies to drive scientific advancements, improve patient outcomes, and shape the future of healthcare.
Others
MoreNews 2024-10-31
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Recently, Porton Pharma has achieved a significant capacity breakthrough at its GMP manufacturing facility in Fengxian, Shanghai, China, further enhancing its production capabilities and technological strength in new modality areas such as peptide and oligonucleotide drugs. This upgrade represents an important step in Porton's commitment to becoming a leading global CDMO company.
News 2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
On October 24, 2024, Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.